Saxenda is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with comorbidities Erectile dysfunction is not listed amongst known adverse effects in the Summary of Product Characteristics or clinical trial data Obesity itself is a well-established risk factor for erectile dysfunction through vascular, hormonal, and metabolic mechanisms Weight loss achieved with Saxenda may actually improve erectile function over time as metabolic health improves Common Saxenda side effects include gastrointestinal symptoms, which typically diminish over time and may indirectly affect sexual wellbeing Patients experiencing new sexual health concerns should consult their GP for thorough assessment rather than discontinuing treatment without medical guidance Table of Contents Understanding Saxenda and Its Primary Effects Saxenda (liraglutide 3.0 mg) is a prescription medicine licensed in the UK for weight management in adults with obesity or those who are overweight with weight-related health conditions
[DOI] [Google Scholar] 93.Bartowsky E.J., Henschke P.A
ADA/EASD: Management of hyperglycaemia in type 2 diabetes, 2015: a patientcentred approach
In research, CJC-1295 (No DAC) has been associated with stronger GH releases while Ipamorelin has been studied for sustaining a steady, regular release pattern
Ensuring complete care for dark spots and photoaging 100% Authentic
Triggering mechanisms in epilepsy, the electroclinical point of view
